Actualités

Merck's second quarter was marked by continued sales growth, primarily driven by the strength of its oncology portfolio and contributions from new product launches. Management credited higher demand for KEYTRUDA in both early-stage and metastatic cancers and robust performance in Animal Health as core drivers. CFO Caroline Litchfield highlighted, “Our strong commercial and operational execution continues to drive near-term performance while we invest in our outstanding pipeline.” While market re

The drugmaker's operating numbers are near the top of its class, but its stock performance is lagging the pack. Is the market seeing a risk that the fundamentals are missing.

Healthcare stocks were higher late Wednesday afternoon, with the NYSE Healthcare Index up 0.2% and t

Management raised its full-year forecast, but the market seems to be asking for more than a higher target.

Bristol Myers growth portfolio now accounts for 56% of revenues, led by key drugs, including Opdivo Qvantig, Reblozyl and Breyanzi, helping offset generic erosion.

RAS mutations fuel nearly a third of all cancers, and one biotech has quietly built the deepest late-stage pipeline targeting them. Now the biggest names in pharma are circling, and the math on who can actually write the check gets complicated fast.

With CPI dropping at 8:30 AM and the Strait of Hormuz near shutdown, Wall Street faces a pivotal morning that could swing stocks sharply in either direction, and analysts at Deutsche Bank, Oppenheimer, Berenberg, and others are already repositioning ahead of the numbers.

Infinimmune is targeting first-in-human studies with its longer-lasting monoclonal antibodies in 2027.

This healthcare giant is on a serious run, but with the stock trading at a peak, investors must decide if the powerful business engine has more fuel or if the price has already burned it all.

Pfizer sent shareholders a fortune in cash, yet the stock fell far behind the market, forcing a hard question about what all that money truly bought.

Oncology and animal health drove $16.6B revenue growth amid upcoming patent expirations.

Eli Lilly's growth is huge, but on its latest call, analysts tested whether the next chapter can possibly live up to the last one.

The case for more upside rests on its obesity pill, and what changed is not the drug but who can now write it and who can now pay for it.

If you hold shares, you're already exposed to a potential future where the stock is either far higher or far lower, and the options market is pricing both as real possibilities.

Positive readouts in cancer and cardiac drug trials could keep the rally going. Sizing up the stakes for Merck, Moderna, Summit Therapeutics, and more.

Merck (MRK) is back in focus after a run of product and earnings headlines. Fresh approvals and label expansion efforts for KEYTRUDA and ENFLONSIA now sit alongside a raised 2026 revenue outlook and recent acquisition charges. See our latest analysis for Merck. Merck’s share price has moved to US$128.37 after a strong run, with a 90 day share price return of 15.25% and a 1 year total shareholder return of 65.06%, suggesting momentum has been building as approvals, trial readouts and raised...

By Anna Szymanski August 7 (Reuters) - Your weekly market recap, with reading, watching and listening recommendations from the ROI team From the Editor Tech earnings hogged the spotlight this week, as

Positive readouts in cancer and cardiac drug trials could keep the rally going. Sizing up the stakes for Merck, Moderna, Summit Therapeutics, and more.

The company says it expects to have mFlusiva ready for the upcoming 2026-2027 flu season, which runs from roughly October to May.

Ligand Pharmaceuticals (NASDAQ:LGND) reported second-quarter 2026 results marked by higher royalty revenue and adjusted earnings, while highlighting the post-quarter close of its XOMA Royalty acquisition and a $700 million zero-coupon convertible-note offering. Total revenue rose 34% year over year

Revolution Medicines posts a wider-than-expected loss in Q2 and raises its 2026 expense outlook again as investors weigh higher spending and pipeline progress.

Pfizer carries one of Big Pharma's fattest yields while Merck burns cash on deals to secure its next growth era. Which trade-off actually serves income investors better after both companies reported earnings?

Ligand stock bounded out of a profit-taking zone Thursday on a strong second-quarter report and an earnings guidance hike.

Merck has outperformed the broader market over the past year, and analysts remain optimistic about the stock.

Merck KGaA (ETR:MRK) reported accelerating organic sales and earnings growth in the second quarter of 2026, led by Life Science and Electronics, and raised its full-year outlook for sales, EBITDA pre and earnings per share. Group net sales rose 3.4% year over year to €5.434 billion. Organic sales g

Based on the average brokerage recommendation (ABR), Merck (MRK) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

Moby summary of Arcus Biosciences, Inc.'s Q2 2026 earnings call

This study miss marks a setback for Gilead’s Trodelvy expansion plans, which include both mono and combination therapy approaches.

Investing.com-- Merck clocked a stronger second-quarter adjusted profit on Tuesday, aided by strong performances in its life science and electronics divisions, with the company also raising its annual profit outlook.

The group pointed to stronger demand in the life-science and electronics markets and resilience in its healthcare operations.